Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

VX-950 is a potent, selective, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3-4A serine protease, and it demonstrated excellent antiviral activity both in genotype 1b HCV replicon cells (50% inhibitory concentration [IC(50)] = 354 nM) and in human fetal hepatocytes infected with genotyp...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Perni, Robert B., Almquist, Susan J., Byrn, Randal A., Chandorkar, Gurudatt, Chaturvedi, Pravin R., Courtney, Lawrence F., Decker, Caroline J., Dinehart, Kirk, Gates, Cynthia A., Harbeson, Scott L., Heiser, Angela, Kalkeri, Gururaj, Kolaczkowski, Elaine, Lin, Kai, Luong, Yu-Ping, Rao, B. Govinda, Taylor, William P., Thomson, John A., Tung, Roger D., Wei, Yunyi, Kwong, Ann D., Lin, Chao
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2006
Matèries:
Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1426435/
https://ncbi.nlm.nih.gov/pubmed/16495249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.50.3.899-909.2006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars